SNY: Sanofi Aventis Price-to-Revenue Multiple

Corporate company logo of Sanofi Aventis (SNY)

Regarding the price-to-sales ratio, this chart on GURU.Markets shows that the metric is fixed at 2.20. Patent barriers and costly biotechnologies serve as a moat for the business. A network of modern plants in the US and Europe guarantees production stability. Monopoly rights to unique therapies allow Sanofi (SNY) to maintain its premium pricing power.

Sanofi (SNY): P/S Multiple from 07/04/2022 to 11/13/2026

Metric breakdowns and analytics for Sanofi Aventis (SNY)

- stock price and consensus target price:
Share Price sanofi.com|SNY - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Sanofi Aventis|SNY - Total Company Value
- book capitalization data:
Net Assets per Share Sanofi|SNY - Book Capitalization|Market Capitalization to Book Value Ratio sanofi.com|SNY - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Sanofi|SNY - Long-Term Debt to Equity|Current Liabilities to Capital Sanofi Group|SNY - Company Aggregate Debts|Debts to Book Capitalization Ratio Sanofi Aventis|SNY - Company Long-Term Debts|Short-Term Debt Volume Sanofi|Interim Coverage Ratio sanofi.com
- net income and valuation ratios data:
SNY - Company Net Income|Net Profit Forecast Sanofi|SNY - Price to Earnings Ratio|Projected Price to Earnings Ratio Sanofi SA|SNY - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Sanofi Aventis|SNY - Operating profit EBITDA|Earnings per share for the trailing year Sanofi|SNY - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth sanofi.com|SNY - Earnings per share growth in current year|Expected earnings per share trend next year Sanofi
- issuer revenue and sales details:
SNY - Company Revenue|Company Future Sales Volume sanofi.com|SNY - P/S Multiple|Forward P/S Multiple Sanofi Aventis
General company analysis:sanofi.com - SNY
Manufactured products of Sanofi S.A.

The P/S ratio determines the market value of Sanofi (SNY) relative to its annual revenue, measuring the premium investors are willing to pay for every euro of sales. For this veteran European manufacturer of vaccines and life-saving medicines, the price/sales ratio trend serves as an indicator of how closely the market valuation aligns with real commercial resilience and global trust in the company's brand.

Competing companies

lilly.com - Market Cap to Revenue Ratio|P/S Multiple ABBV (AbbVie)|Price-to-Revenue Multiple AstraZeneca Plc|NVS - Price-to-Revenue Ratio|Price-to-Revenue Coefficient MSD MRK|NVO: P/S Multiple|amgen.com (AMGN) - P/S Multiple|Price-to-Revenue Ratio Pfizer|Market Cap to Revenue Ratio BMY (Bristol Myers Squibb Company)|Price-to-Revenue Ratio GSK plc (GSK)|TAK - Price to Sales|P/S Multiple TEVA (Teva Pharmaceutical Industries)|RDY (drreddys.com) - Price-to-Sales Ratio|Viatris - P/S Multiple|Price-to-Revenue Coefficient Roivant ROIV|Zai Lab Ltd. (ZLAB) - Price-to-Revenue Ratio|BHC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Cosmos Health Inc.